3 German institutions formed a framework agreement to advance innovative radiopharmaceutical cancer treatments.

ITM, TUM, and TUM University Hospital have established a framework agreement to enhance innovative radiopharmaceutical treatments for cancer. This collaboration combines ITM's production of medical radioisotopes, TUM's research in nuclear physics, and TUM Hospital's clinical expertise. The goal is to expedite nuclear medicine projects and broaden the availability of targeted radiopharmaceuticals, ultimately improving outcomes for cancer patients.

October 24, 2024
3 Articles

Further Reading